Deafness-encephaloneuropathy-obesity-valvulopathy syndrome

Deafness-encephaloneuropathy-obesity-valvulopathy syndrome, also known as Megarbane syndrome, is an extremely rare multisystem disorder characterized by the combination of sensorineural hearing loss, central nervous system abnormalities (encephalopathy), peripheral neuropathy, obesity, and cardiac valvular disease (valvulopathy). This condition affects multiple organ systems including the auditory system, the central and peripheral nervous systems, the cardiovascular system, and metabolic regulation. Patients typically present with progressive sensorineural deafness, intellectual disability or developmental delay related to encephalopathy, peripheral nerve dysfunction, early-onset obesity, and abnormalities of the heart valves that may lead to cardiac complications. The syndrome was first described by Megarbane and colleagues, and only a very small number of cases have been reported in the medical literature. The underlying genetic cause has not been fully elucidated, though an autosomal recessive inheritance pattern has been suggested based on the reported familial cases. Due to the extreme rarity of this condition, there is no specific targeted therapy available. Management is supportive and multidisciplinary, involving audiological intervention (such as hearing aids or cochlear implants), neurological monitoring and rehabilitation, cardiac surveillance and management of valvular disease, and dietary and metabolic support for obesity. Early diagnosis and coordinated care among specialists in genetics, cardiology, neurology, and audiology are essential to optimize outcomes for affected individuals.

Common questions about Deafness-encephaloneuropathy-obesity-valvulopathy syndrome